In today’s briefing:
- PT Medikaloka Hermina (HEAL IJ) – Women & Children with Increasing Intensity
- Daiichi Sankyo (4568 JP): Strong Beneficiary of Cancer Drug Enhertu; High Hope for Research Pipeline
- Coeptis Therapeutics Inc. (COEP) YE22 1Q23 & DeSPAC 29062023
PT Medikaloka Hermina (HEAL IJ) – Women & Children with Increasing Intensity
- Medikaloka Hermina (HEAL IJ) saw a strong recovery in patient volumes in 1Q2023, with margins starting to normalise from COVID highs and occupancy rates picking up.
- The company is back on an expansion track and recently secured the first hospital in the new capital next year with two new hospitals planned to open this year.
- Medikaloka Hermina continues to focus on women & children and JKN patients but is also expanding into more intensive specialist treatments to drive profits. Valuations remain attractive versus peers.
Daiichi Sankyo (4568 JP): Strong Beneficiary of Cancer Drug Enhertu; High Hope for Research Pipeline
- In FY23, Daiichi Sankyo (4568 JP) recorded Enhertu product revenue growth of 218% YoY to ¥208B, 4% ahead of forecast, driven by indication expansion and strong market penetration in US.
- For FY24, Enhertu product revenue is expected to increase 54% YoY to ¥320B, driven by higher utilization in HER2 positive and HER2 low breast cancer in US.
- Daiichi Sankyo has two more drug candidates in late-stage trials for various cancers. Contribution of oncology to total revenue is expected to increase to 45% in FY26 from 20% now.
Coeptis Therapeutics Inc. (COEP) YE22 1Q23 & DeSPAC 29062023
- C&CE 1Q23A $2.1m, burn 1Q $1.6m, S-1MEF filed for raise
- YE22A Opex $34.2m vs. $14.1 y/y, Δ is redemptions/merger costs
- Warrants booked as liabilities (SEC de-SPAC ruling Apr 12, 2021)
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
